Mapping the HLA association in Behçet's disease: A role for tumor necrosis factor polymorphisms?

Arthritis and Rheumatism

Volumn 48, Issue 3, 2003, Pages 807-813

  Ahmad, Tariq ^a,h   Wallace, Graham R ^b   James, Teifi ^c   Neville, Matt ^a   Bunce, Mike ^d   Mulcahy Hawes, Kim ^a   Armuzzi, Alessandro ^a   Crawshaw, Jonathan ^a   Fortune, Farida ^e   Walton, Robert ^a   Stanford, Miles R ^b   Welsh, Ken I ^f   Marshall, Sara E ^g   Jewell, Derek P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^d Dynal Biotech   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

^h RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLELE; ALLELISM; ARTICLE; BEHCET DISEASE; CAUCASIAN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ETHNIC GROUP; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HLA B GENE; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; TNF GENE; UNITED KINGDOM;

EID: 0037333975     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10815     Document Type: Article

References (50)

1. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
2. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995;38:426-33.
3. Mege JL, Dilsen N, Sanguedolce V, Gül A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
4. Koné-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. J Pediatr 1999;135:89-93.
5. Gül A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 2000;59:622-5.
6. Ohno S, Asanuma T, Sugiura S, Wakisaka A, Aizawa M, Itakura K. HLA-Bw51 and Behçet's disease [letter]. JAMA 1978;240:529.
7. Mizuki N, Inoko H, Ando H, Nakamura S, Kashiwase K, Akaza T, et al. Behçet's disease associated with one of the HLA-B51 subantigens, HLA-B*5101. Am J Ophthalmol 1993;116:406-9.
8. Kera J, Mizuki N, Ota M, Katsuyama Y, Pivetti-Pezzi P, Ohno S, et al. Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behçet's disease in Italian patients. Tissue Antigens 1999;54:565-71.
9. Gül A, Hajeer AH, Worthington J, Barrett JH, Ollier WER, Silman AJ. Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001;44:239-40.
10. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease. Tissue Antigens 1999;54:264-72.
11. Gül A, Uyar FA, Inanc M, Ocal L, Tugal-Tutkun I, Aral O, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet's disease. Rheumatology (Oxford) 2001;40:668-72.
12. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
13. Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, et al. Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 2000;41:3702-8.
14. Mizuki N, Yabuki K, Ota M, Verity D, Katsuyama Y, Ando H, et al. Microsatellite mapping of a susceptible locus within the HLA region for Behçet's disease using Jordanian patients. Hum Immunol 2001;62:186-90.
15. Ota M, Mizuki N, Katsuyama Y, Tamiya G, Shiina T, Oka A, et al. The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999;64:1406-10.
16. Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A 1997;94: 1298-303.
17. Wallace GR, Verity DH, Delamaine LJ, Ohno S, Inoko H, Ota M, et al. MIC-A allele profiles and HLA class I associations in Behçet's disease. Immunogenetics 1999;49:613-7.
18. Kimura T, Goto K, Yabuki K, Mizuki N, Tamiya G, Sato M, et al. Microsatellite polymorphism within the MICB gene among Japanese patients with Behçet's disease. Hum Immunol 1998;59:500-2.
19. Gül A, Hajeer AH, Worthington J, Ollier WER, Silman AJ. Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23. Arthritis Rheum 2001;44:2693-6.
20. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, et al. Role of γδ T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997;107:241-7.
21. Ruuls SR, Sedgwick JD. Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Am J Hum Genet 1999;65:294-301.
22. Wonderling D, Langham S, Buxton M, Normand C, McDermott C. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses. BMJ 1996;312:1274-8.
23. Welsh K, Bunce M. Molecular typing for the MHC with PCR-SSP. Rev Immunogenet 1999;1:157-76.
24. Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard TR, Crawshaw J, Armuzzi A, et al. High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens 2002;60:164-79.
25. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998;51:605-12.
26. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
27. Fanning GC, Bunce M, Black CM, Welsh KI. Polymerase chain reaction haplotyping using 3′ mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumor necrosis factor and lymphotoxin alpha. Tissue Antigens 1997;50:23-31.
28. Milner CM, Campbell RD. Structure and expression of the three MHC-linked HSP70 genes. Immunogenetics 1990;32:242-51.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
30. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994;43:18-27.
31. Schlesselman JJ. Case-control studies: design, conduct, analysis. Oxford: Oxford University Press, 1982.
32. Akey J, Jin L, Xiong M. Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 2001;9: 291-300.
33. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001;29:229-32.
34. Choukri F, Chakib A, Himmich H, Hue S, Caillat-Zucman S. HLA-B*51 and B*15 alleles confer predisposition to Behçet's disease in Moroccan patients. Hum Immunol 2001;62:180-5.
35. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91-9.
36. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
37. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995;46:32-41.
38. Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998;52:359-67.
39. Skoog T, van't Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J, et al. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet 1999;8:1443-9.
40. Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001;2:135-44.
41. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8.
42. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
43. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease [letter]. Lancet 2001;358:295-6.
44. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9.
45. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8.
46. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001;60:637.
47. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
48. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95.
49. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996;124:891-3.
50. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986;40:747-54.